Loading clinical trials...
Loading clinical trials...
A Phase 1/2a Trial to Evaluate the Safety/Tolerability and Immunogenicity of Homologous Ad26 Mosaic Vector Regimens or Ad26 Mosaic and MVA Mosaic Heterologous Vector Regimens, With High-Dose, Low-Dose or no Clade C gp140 Protein Plus Adjuvant for HIV Prevention
Conditions
Interventions
Ad26.Mos.HIV
MVA-Mosaic
+3 more
Locations
12
United States
Aurora, Colorado, United States
Miami, Florida, United States
Rockville, Maryland, United States
Boston, Massachusetts, United States
Austin, Texas, United States
Kigali, Rwanda
Start Date
December 22, 2014
Primary Completion Date
August 29, 2017
Completion Date
March 28, 2022
Last Updated
February 4, 2025
NCT06716502
NCT00090662
NCT07310264
NCT06290258
NCT07483606
NCT06342713
Lead Sponsor
Janssen Vaccines & Prevention B.V.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions